CfDNA in Hereditary And High-risk Malignancies 2

RecruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

April 19, 2024

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2031

Conditions
Hereditary Cancer Syndrome
Interventions
DIAGNOSTIC_TEST

Cell-free DNA analysis

Analysis of cell-free DNA in blood plasma will involve targeted sequencing of key cancer-related genes, cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq), and shallow whole genome sequencing (sWGS).

Trial Locations (8)

V5Z 4E6

NOT_YET_RECRUITING

BC Cancer Agency, Vancouver

A1B 3V6

NOT_YET_RECRUITING

Eastern Health, St. John's

B3K 6R8

NOT_YET_RECRUITING

IWK Health Centre, Halifax

M5G 1E8

NOT_YET_RECRUITING

The Hospital for Sick Children, Toronto

M5G 1X5

RECRUITING

Sinai Health System, Toronto

M5G 2M9

RECRUITING

University Health Network, Toronto

M5S 1B2

NOT_YET_RECRUITING

Women's College Hospital, Toronto

H3T 1E2

NOT_YET_RECRUITING

Jewish General Hospital, Montreal

Sponsors
All Listed Sponsors
collaborator

British Columbia Cancer Agency

OTHER

collaborator

Eastern Health

OTHER

collaborator

IWK Health Centre

OTHER

collaborator

Jewish General Hospital

OTHER

collaborator

Sinai Health System

OTHER

collaborator

The Hospital for Sick Children

OTHER

lead

University Health Network, Toronto

OTHER